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Abstract
Background: Multiple sclerosis (MS) is associated with ectopic lymphoid follicle formation. Podoplanin+
(lymphatic marker) T helper17 (Th17) cells and B cell aggregates have been implicated in the formation of tertiary
lymphoid organs (TLOs) in MS and experimental autoimmune encephalitis (EAE). Since podoplanin expressed by
Th17 cells in MS brains is also expressed by lymphatic endothelium, we investigated whether the pathophysiology
of MS involves inductions of lymphatic proteins in the inflamed neurovasculature.
Methods: We assessed the protein levels of lymphatic vessel endothelial hyaluronan receptor and podoplanin,
which are specific to the lymphatic system and prospero-homeobox protein-1, angiopoietin-2, vascular endothelial
growth factor-D, vascular endothelial growth factor receptor-3, which are expressed by both lymphatic
endothelium and neurons. Levels of these proteins were measured in postmortem brains and sera from MS
patients, in the myelin proteolipid protein (PLP)-induced EAE and Theiler’s murine encephalomyelitis virus (TMEV)
induced demyelinating disease (TMEV-IDD) mouse models and in cell culture models of inflamed neurovasculature.
Results and conclusions: Intense staining for LYVE-1 was found in neurons of a subset of MS patients using
immunohistochemical approaches. The lymphatic protein, podoplanin, was highly expressed in perivascular
inflammatory lesions indicating signaling cross-talks between inflamed brain vasculature and lymphatic proteins in
MS. The profiles of these proteins in MS patient sera discriminated between relapsing remitting MS from secondary
progressive MS and normal patients. The in vivo findings were confirmed in the in vitro cell culture models of
neuroinflammation.
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Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease with neurodegeneration characterized by demyelin-
ating plaques, neuronal, and axonal loss [1-3]. The precise
etiology and pathophysiology for MS remain unknown.
Many key steps in MS pathogenesis including the break-
down of the blood–brain barrier and the extravasation of
immune cells into the brain parenchyma involve interac-
tions with the vascular endothelium [4-12]. The enhanced
spatial resolution of ultra-high field 7T magnetic resonance
imaging (MRI) has demonstrated that >80% of white
matter lesions in MS patients have a central vein (21) and
natalizumab, an anti-α4 integrin monoclonal antibody that
blocks cell-cell interactions between VLA-4 (α4β1 integ-
rin, CD49d/CD29 heterodimer, also known as very late
antigen-4) expressed on activated immune cells and vascular
cell adhesion molecule (VCAM-1) expressed on the vas-
cular endothelium is an approved drug for treating MS.
Although the brain lacks ‘classical’ lymphatics, interstitial
fluid and solutes have been shown to drain along 150–200
nm wide ‘lacunae’ in the basement membranes of arteries
and capillary walls [13-18]. The role of any of lymphatic
proteins in MS pathogenesis has not been extensively
investigated.
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Moreover, tertiary lymphoid organs (TLOs) with ectopic
lymphoid follicles have been observed in the central
nervous system (CNS) of MS patients as well as in animal
models of MS [19-24]. The characteristic features of TLOs
include compartmentalization of T and B cells, presence
of lymphatic vessels, and high endothelial venules (HEVs)
[24-30]. Th17 cells and B cells were shown to be the main
contributors in the formation of these structures. However,
the cellular mechanisms involved in their development and
their function was not yet clear. It has been suggested that
TLOs participate in antigen presentation and contribute to
the progression of the disease to chronic stage (probably
from RRMS to secondary-progressive MS (SPMS)) [24].
However, formation of HEVs has not been reported in MS
[20,31,32] and it is not known whether these TLOs contain
active lymphatic vascular structures. The lack of reliable
lymphatic markers to distinguish between blood and
lymphatic vasculature did not permit such studies until
recently. The availability and validation of novel lymphatic
marker proteins (podoplanin/D2-40, LYVE-1, VEGFR-3,
VEGF-D, Ang-2) and transcription factors (Fox-C2, Prox-1)
[33-36] have rapidly expanded our understanding of
lymphatics and allow investigation of their roles in MS
pathophysiology. While LYVE-1, podoplanin, and Fox-
C2 are lymphatic-specific, Prox-1, VEGFR-3, VEGF-D,
and Ang-2 also participate in neuronal function and
development [37-42].
Our working hypothesis is that alterations in lymphatic
proteins may play a critical role in tertiary lymphoid forma-
tion in MS. The purpose of this study was to investigate
the role of lymphatic vessel endothelial hyaluronan recep-
tor and podoplanin, which are specific to the lymphatic
system, and prospero-homeobox protein-1, angiopoietin-2,
vascular endothelial growth factor-D, and vascular endo-
thelial growth factor receptor-3, which are expressed by
both lymphatic endothelium and neurons in MS patho-
genesis. Lymphatic protein expression was measured in
postmortem brains and sera from MS patients, in the mye-
lin proteolipid protein (PLP)-induced EAE and Theiler’s
murine encephalomyelitis virus (TMEV) induced demye-
linating disease (TMEV-IDD) mouse models and in cell
culture models of neurovasculature inflammation.
Methods
Cell culture
Human brain endothelial cell line (HBMEC-3, provided
by Dr. Anat Erdreich Epstein, Saban Research Institute at
Children’s Hospital Los Angeles, University of Southern
California, USA) was cultured in RPMI medium supple-
mented with 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin/amphotericin (PSA). Human neuronal like
cell line (SHSY-5Y) was cultured in DMEM supplemented
with 10% FCS and 1% PSA.
Animal models of MS (PLP-EAE and TMEV-IDD)
and EAE induction
All animal experiments were performed according to
Institutional Animal Care and Use (ACUC) Committee
guidelines at the Louisiana State University Health Sciences
Center-Shreveport with approved animal protocols.
For PLP-EAE, three or four female SJL/J mice (4 weeks,
Jackson Labs, Bar Harbor, ME, USA) were randomly
chosen from a group of mice subcutaneously sensitized
with 100 nmol of myelin proteolipid protein (PLP)139–151
peptide (VSLGKWLGHPDKF, United BioSystems Inc.,
Rockville, MD, USA) emulsified in complete Freund’s
adjuvant, as described [43]. Briefly, both brains and sera
from the randomly selected PLP-EAE mice were harvested
on day 14 post sensitization. Clinical scores of PLP-EAE
animals were evaluated daily based on the following scale:
0, no sign; 1, paralyzed tail; 2, mild hind limb paresis;
3, moderate hind limb paralysis; 4, complete hind limb
paralysis; and 5, quadriplegia or moribund.
For TMEV-IDD, three or four mice were randomly
chosen from a group of mice infected intra-cerebrally
with 2×105 plaque forming units (PFU) of TMEV. Brains
and sera were harvested on day 35 after infection. Clinical
scores of TMEV-IDD animals were evaluated daily based
on examining impairment of righting reflex: proximal end
of mouse tail was grasped and twisted to the right and
then to left. The following scale was used: 0, a healthy
mouse resists being turned over; 1, the mouse is flipped
onto to its back but immediately rights itself; 1.5, the
mouse is flipped onto its back but immediately rights itself
on both sides; 2, the mouse rights itself in 1 to 5 s; 3,
righting takes >5 s; 4, the mouse cannot right itself.
MS specimens
De-identified postmortem MS brain specimens were ob-
tained from the Human Brain and Spinal Fluid Resource
Center (Neurology Research, Los Angeles, CA, USA). The
banked control brain tissues included donors with brain
disease. MS brain samples were obtained from patients
clinically diagnosed with RRMS. Details of clinical diagno-
sis, gross, and micro-neuropathology of postmortem MS
brain samples are indicated in Additional file 1: Table S1.
De-identified samples of control, RRMS, and SPMS sera
were obtained from the MS Center at the University at
Buffalo.
Western blots
Five microliters of PLP-EAE, TMEV-IDD, RRMS, SPMS,
and respective controls’ serum specimens were immu-
noblotted for Prox-1, D2-40, LYVE-1, Ang-2, VEGFR-3, or
VEGF-D. Control, PLP-EAE, TMEV-IDD mouse brains,
and postmortem MS brain samples were homogenized in
modified RIPA buffer (0.25 M sucrose, 50 mM Tris base,
150 mM NaCl, 1 mM EDTA, 1 mM MgCl2, 10 mM KCl,
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1% NP40, and 1% Tween-20 supplemented with protease
and phosphatase inhibitor cocktail-Sigma) and protein
content was measured by the Lowry method. Equal
amount of protein from these samples was separated on
SDS-PAGE and immunoblotted with PROX-1, D2-40,
LYVE-1, VEGFR-3, VEGF-D, and Ang-2.
Antibodies
Angiopoietin-2 (Cat no. ab65835, Abcam), Podoplanin/
D2-40 (Cat no. SIG-3730, Covance), LYVE-1 (for immuno-
fluorescence) (Cat no. ab14917, Abcam), LYVE-1 (an in-
house antibody), Prox-1 (Cat no. PRB-238C, Covance),
VEGFR-3 (Cat no. AB1875, Chemicon), VEGF-D (Cat
no. MAB286, R&D), Pan axonal neurofilament marker
(Cat no. SMI311, Sternberger Monoclonals Inc.).
Immunohistochemistry
Postmortem MS brain tissue was fixed in 4% parafor-
maldehyde and 3 μm sections were processed through
alcohol/xylene followed by antigen retrieval solution
(Pro-histo), washed, and incubated in primary antibodies
against LYVE-1 and D2-40 for overnight at 4°C. Later
sections were washed and incubated with super sensitive
link label IHC detection system (Cat no. QP900-9L,
Biogenex) for 30′ with three washes in between. Later
sections were washed and developed using di-amino
benzidine and photographed. All primary antibody dilu-
tions were performed in pro-histo amplifying antibody dilu-
tion buffer (Pro-Histo, Cat no. AA3).
Double immunofluorescence
Sections were washed and incubated in a cocktail of
primaries against SMI311 and LYVE-1 overnight at 4°C.
Negative controls included omitting primary antibodies.
Later sections were washed three times and incubated in
cocktail of AlexaFluor488 and Cy-3 conjugated secondary
antibodies for 2 h at room temperature. All primary and
secondary antibody dilutions were performed in pro-histo
amplifying antibody dilution buffer. Later sections were
washed and mounted using mounting media with DAPI
and observed under Olympus fluorescent microscope.
Cell ELISA
At confluence HBMEC3-brain endothelium and SHSY-5Y
neurons were treated with 25 ng/mL of TNF-α, IL-1β,
IFN-γ, and IL-3 for 24 h. After treatment, cell ELISA for
podoplanin (D2-40), LYVE-1, PROX-1, VEGFR3, VEGF-D,
and Ang-2 was performed according to previously pub-
lished protocol [44]. Briefly, cells were fixed for 5 min with
1% PFA, washed, and incubated in primary antibodies
diluted in HBSS/DPBS/5%FCS for 2 h at 37°C. Later cells
were washed three times with HBSS/DPBS/1% FCS and
incubated in HRP conjugated secondary antibodies for 1 h
at 37°C. Later cells were washed three times and incubated
in substrate combination of TMB/H2O2. Reaction was
stopped by addition of 8N H2SO4 and the plates were read
on an ELISA plate reader at 450 nm. Absorbance of
untreated control cells was used as the baseline 100%. For
Prox-1 cell ELISA, an additional step of treating cells with
0.25% Triton X-100 for 5′ was added after fixation to
permeabilize the cells.
Heat map and PCA
Principal component analysis (PCA) for expression data of
marker proteins was conducted using R-software (v2.15.1,
prcomp package). To study patterns of lymphatic bio-
marker expression in the brain, we converted densitometry
data into heat maps, using ‘R-software’ (R Development
core team, 2012 [45]). We conducted ‘supervised’ pair-wise
comparisons of western blot data between control and MS
samples [46] and drew heat map and dendrogram using R
version 2.15.1 and the program package ‘stats’ and ‘pvclust’
(R Core team, 2012). We also conducted ‘unsupervised’
PCA by entering western blot data of control and MS
samples without grouping with R and the program
package ‘prcomp’ [47-49]. The proportions of variance
and factor loadings for principal components (PC) were
also calculated at the same time [47-49]. Heat maps and
hierarchical clustering dendrograms were generated using
the R-Software package.
Statistical analysis
The independent samples t test with two-tailed P value
was used to check significance between two groups, and
one-way ANOVA with Dunnetts post-hoc test was used
to assess the significance between more than two groups.
Results
Neuro-lymphatic proteins in postmortem RRMS brain
and RRMS and SPMS sera
Expression of neuro-lymphatic proteins in postmortem
MS brain
Western blot analysis showed significant increase in the
levels D2-40 (P=0.04), LYVE-1 (P=0.018), Prox-1 (P=0.046),
VEGF-D (P=0.011), and Ang-2 (P=0.01) were observed
in RRMS samples compared to controls. VEGFR-3 levels
were significantly lower (P=0.034) in human MS brain tis-
sue possibly indicating neuronal degeneration (Figure 1A,
Additional file 2: Figure S1A).
Expression of neuro-lymphatic proteins in sera from RRMS
and SPMS patients
We found increased expression of D2-40 (P=0.0018),
LYVE-1 (P=0.028), VEGFR-3 (P=0.039), VEGF-D (P=0.014),
and Ang-2 (P=0.0164) in RRMS sera, Prox-1 levels were
decreased (P=0.0075) in RRMS serum versus controls
(Figure 1B, Additional file 2: Figure S1B).
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D2-40 and VEGF-D (P=0.05) were increased in SPMS
sera (P=0.048) whereas LYVE-1 (P=0.004) and Prox-1
(P=0.001) decreased. No differences were found in Ang-2
or VEGFR-3 levels in SPMS sera (Figure 1B, Additional
file 2: Figure S1B).
Immunohistochemistry of lymphatic specific proteins
LYVE-1 and D2-40 in RRMS brains
Since we observed a significant increase in lymphatic spe-
cific D2-40 and LYVE-1 expression in western blot analysis,
we performed immunohistochemistry for D2-40 and LYVE-1
to understand the tissue distribution of these proteins.
Immunostaining for D2-40 and LYVE-1 in RRMS brain
tissue showed prominent vascular staining. MS plaques
showed greater D2-40 immunostaining compared with
non-plaque regions or control brain tissue (Figure 2A,
Additional file 3: Figure S2A). While normal brains tissue
showed D2-40 immunostaining closely associated with
the vascular lining of blood vessels, MS brain tissue was in-
tense with perivascular parenchyma. Immunohistochemical
Figure 1 Western blots of Neuro-Lymphatic proteins in MS brains and sera. (A) Western blots from human control and MS postmortem
brain tissue. Con=Postmortem human control brain tissue, MS=Postmortem human RRMS brain tissue. Con n=5, MS n=9, *P <0.05 considered
significant. Table shows the P value between two groups. Two-way ANOVA with unpaired T-test between two individual groups. (B) Western
blots of RRMS and SPMS patients’ serum. Table shows the P value between two groups. Con n=4, RRMS n=5, SPMS n=5. *P <0.05 is considered
statistically significant. Two-way ANOVA with unpaired T-test between two individual groups.
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staining of MS brain sections showed increased D2-40
staining intensity on and around brain microvessels
consistent with D2-40 as a possible marker of microvessel
inflammation in MS brain tissue.
LYVE-1 vascular immunostaining was also more intense
in MS than in controls which showed low LYVE-1 immu-
noreactivity. Apart from vessel structures, neuronal LYVE-1
staining was observed in several MS samples (3816, 3422,
Figure 2 Immunostaining of LYVE-1 and Podoplanin (D2-40) in MS brains. (A) D2-40 Immunostaining of control and MS human postmortem
brain tissue. D2-40 immunostaining was mainly localized to the inner wall of brain endothelium in normal brain tissue sections and at perivascular
inflammatory regions in MS brain tissue sections. Magnification 40×. (B) LYVE-1 immunostaining in control and MS human postmortem brain tissue.
LYVE-1 immunostaining was not confined to vasculature in the MS tissue since, neuronal like cells were found to be LYVE-1+ in sample numbers 572,
3422, and 3816. Inset shows the axonal positivity of LYVE-1 in MS brain tissue. Magnification 40×. (C) Double immunofluorescence analysis of LYVE-1
and SMI311 in patient samples 3422 and 572. We observed a strong co-localization of SMI311 (recognizes both neuronal bodies and axons) stained in
green (Alex-488) with LYVE-1 stained in red (cy3) in RRMS brain tissue samples. Furthermore, SMI311 was also observed to be co-localized on axons.
LYVE-1 staining was primarily confined around the axons indicating oligodendrocyte/myelin positivity. Inset shows a higher magnification of SMI311
co-localization with axonal structures in MS 572 (magnification 100×). (D) LYVE-1 immunofluorescence also showed higher numbers of
LYVE-1+ immune cell infiltrates in the MS brain vasculature (572, 3422) compared to controls (4064).
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572, and 2946). Brain parenchyma in MS plaques also
stained intensely for LYVE-1 (Figure 2B, Additional file 3:
Figure S2B).
Apparent neuronal LYVE-1 staining was found in
MS patient samples 572 and 3422, and was confirmed
by double labeling with the neuronal marker ‘SMI311’
(Figure 2C). Further, distinctive peri-axonal LYVE-1
staining showing myelin positivity was observed (sample
3422). Figure 3B (MS sample 3422) inset shows LYVE-1
immunohistochemistry in a consecutive section which
confirms axonal identity. Double-immunofluorescence
confirmed that LYVE-1 staining was co-localized with
peri-axonal oligodendrocyte/myelin (Figure 2C). We also
observed higher numbers of LYVE-1+ immune cells in
the vasculature in MS brain tissue compared to controls
(Figure 2D).
Neuro-lymphatic protein alterations in TMEV-IDD
TMEV-IDD mouse brains had significantly higher levels
of VEGFR3 (P=0.004) and VEGF-D (P=0.019) compared
to controls. No difference in Prox-1, LYVE-1, or Ang-2
levels were observed in brains of TMEV-IDD compared
with controls (Figure 4A, Additional file 4: Figure S3A).
We observed a significant increase in the levels of Prox-1
(P=0.009), VEGFR-3 (P=0.036), VEGF-D (P=0.042), and
Ang-2 (P=0.001) in the sera of TMEV-IDD mice. No
difference in levels of LYVE-1 was observed (Figure 4B,
Additional file 4: Figure S3B).
Neuro-lymphatic protein alterations in PLP EAE
An interesting pattern of ‘lymphatic’ protein expression
was observed in the brains of naïve, CFA, and CFA+PLP-
EAE mice.
Figure 3 Western blots of Neuro-lymphatic proteins in TMEV-IDD mice brains and sera. (A) Western blots of PLP-EAE brains. Con=control,
CFA=Complete Freund’s Adjuvant treated mice. CFA+PLP=Complete Freund’s Adjuvant + Myelin proteolipid protein treated mice. Con n=3, CFA
n=3, CFA+PLP n=4. Table shows the P value between two groups. *P <0.05 is considered statistically significant. Two-way ANOVA with unpaired
T-test between two individual groups. (B) Western blots PLP-EAE sera. Con n=3, CFA n=3, CFA+PLP n=4. Table shows the P value between two
groups. *P <0.05 is considered statistically significant. Two-way ANOVA with unpaired T-test between two individual groups.
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VEGF-D was the only protein (naïve vs. CFA vs. CFA+
PLP) that showed significant increase between naïve, CFA,
and CFA+PLP-EAE brains (naïve vs. CFA, P=0.024; CFA
vs. CFA+PLP, P=0.009; naïve vs. CFA+PLP, P=0.002). No
difference in Ang-2 levels was observed between any of
groups (Figure 3A, Additional file 5: Figure S4A).
CFA induced significantly higher levels of LYVE-1
(P=0.013) and Prox-1 (P=0.045). No significant differences
in LYVE-1 or Prox-1 expression were observed in the
brains of naïve and CFA+PLP-EAE mice.
CFA and CFA+PLP-EAE mice brains had significantly
higher levels of VEGFR3 (naïve vs. CFA, P=0.003; naïve
vs. CFA+PLP-EAE, P=0.019) compared to naïve controls.
However, no difference between CFA versus CFA+PLP-
EAE in VEGFR3 levels was observed.
We also observed changes in ‘lymphatic’ protein ex-
pression in the sera of naïve, CFA, and CFA+PLP-EAE
mice. While CFA significantly decreased levels of LYVE-1
(P=0.046) and VEGF-D (P=0.003), no difference was ob-
served in LYVE-1 and VEGF-D levels between naïve and
CFA+PLP-EAE mice. Both CFA and CFA+PLP-EAE mice
sera had lower levels of VEGFR3 (naïve vs. CFA, P=0.010;
naïve vs. CFA+PLP, P=0.002) compared to controls. How-
ever, no difference between CFA versus CFA+PLP-EAE in
VEGFR3 levels was observed. No difference in Prox-1 or
Ang-2 levels was observed between any of the groups
(Figure 3B, Additional file 5: Figure S4B).
Comparisons of these serum and brain tissue lymphatic
proteins in mouse models and human MS are shown in
Table 1.
Figure 4 Western blots of Neuro-Lymphatic proteins in PLP-EAE mice brains and sera. (A) Western blots from TMEV-IDD brains. Nai=Naïve,
TMEV=TMEV-IDD. Naïve n=3, TMEV n=3. Table shows the P value between two groups. *P <0.05 is considered statistically significant. Two-way
ANOVA with unpaired T-test. (B) Western blots TMEV-IDD sera. Naïve n=3, TMEV n=3. Table shows the P value between two groups. *P <0.05
is considered statistically significant. Two-way ANOVA with unpaired T-test.
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PCA analysis
We hypothesized that lymphatic markers might represent
important biomarkers for demyelinating diseases. We
next conducted PCA of lymphatic markers to determine
whether controls, RRMS, or SPMS samples could be
separated into three distinct groups: Con, RRMS, and
SPMS. PCA was applied to immunoblot densitometry
data of six lymphatic markers in control, RRMS, and SPMS
sera. PC1 and PC2 accounted for >90% of variance (PC1,
61%; PC2, 28%). RRMS and controls could be separated
along the axis defined by PC1, but not PC2, indicating that
PC1 can explain an important part of the variance that
separates RRMS from controls. RRMS and SPMS could be
separated along the axis defined by PC2 but not PC1.
Thus, serum lymphatic markers, as a whole, can be used to
separate these three groups (Figure 5).
To determine which serum lymphatic markers contrib-
ute to PC1 and PC2, we next looked at factor loading
(Additional file 6: Figure S5). We found that Prox-1 was
negatively associated with both PC1 and PC2 values. This
is consistent with western blot analysis, in which Prox-1
expression was decreased in both RRMS and SPMS.
Interestingly, Ang-2 and LYVE-1 were positively associ-
ated with PC1 values and negatively associated with
PC2 values. Again, these results were consistent with
the findings from the inter-group statistical comparisons,
in which Ang-2 and LYVE-1 levels were increased in
RRMS but not SPMS.
Inflammatory cytokines induce differential neuro-lymphatic
protein expression on neurovasculature in vitro
In order to understand the role of inflammation in the
induction of these common neuronal/lymphatic proteins
in neurovasculature, human neurons, and brain endothelial
cells were treated with inflammatory cytokines including
TNF-α, IL-1β, and IFN-γ for 24 h. IL-3 was used as a
positive treatment condition based on previously published
data [50].
HBMEC-3 human brain endothelium
All the treatment conditions including TNF-α (P=0.042),
IL-1β (P=0.008), IFN-γ (P=0.001), and IL-3 (P=0.001)
induced VEGF-D expression in HBMEC-3. IFN-γ in-
duced significant increase in LYVE-1 expression (P=0.001),
whereas IL-3 induced significant increase in Prox-1 expres-
sion (P=0.007). None of the treatment condition induced
D2-40, Ang-2, or VEGFR-3 expression in human brain
endothelium (Figure 6A, Additional file 7: Figure S6A).
SHSY-5Y human neurons
Similar to HBMEC-3 all the cytokines including TNF-α
(P=0.0001), IL-1β (P=0.002), IFN-γ (P=0.002), and IL-3
(P=0.001) induced higher levels of VEGF-D. In addition
to IL-3 (P=0.002), TNF- α (P=0.001), and IFN-γ (P=0.03)
induced higher levels of Prox-1 in SHSY-5Y neurons.
VEGFR-3 expression in SHSY-5Y neurons was induced
by TNF-α (P=0.01), IFN-γ (P=0.03), and IL-3 (P=0.002).
IFN-γ (P=0.003) and IL-3 (P=0.01) induced significantly
higher levels of SHSY-5Y Ang-2 expression (Figure 6B,
Additional file 7: Figure S6B). None of the treatment
conditions induced D2-40 or LYVE-1 expression.
Discussion
While the functional role of neuronal LYVE-1 is still not
clear, several of the common neuro-lymphatic proteins
in the study including Prox-1, VEGFR-3, Ang-2, and
VEGF-D are indispensable for brain development and
neuronal function. For example, induction of neuronal
specific Prox-1 and Mash-1 are crucial for the differenti-
ation of neural stem cells in the developing brain [42].
Prox-1 also controls Notch-1 dependent neurogenesis in
spinal cord [51]. In the developing rat brain VEGFR-3
expression has been observed in forebrain, retina, and
cerebellum [52,53]. Interestingly its expression is enhanced
in the subventricular zone of the stroke lesions in rat brain
[54]. The expression of VEGFR-3 in subventricular zone
suggests its participation in stem cell signaling. Even
Table 1 Western data of D2-40, LYVE-1, Prox-1, VEGFR-3, VEGF-D and Ang-2 levels in MS and its animal models
D2-40 LYVE-1 PROX-1 VEGFR-3 VEGF-D Ang-2
MS brain (RRMS) ↑ ↑ ↑ ↓ ↑ ↑
TMEV brain NA − − ↑ ↑ −
PLP braina NA − − − ↑ −
RRMS serum ↑ ↑ ↓ ↑ ↑ ↑
SPMS serum ↑ − ↓ ↑ ↑ −
TMEV serum NA − ↑ ↑ ↑ ↑
PLP seruma NA − − − − −
Con vs. RRMS human brain samples; Con vs. SPMS and RRMS serum samples; Control vs. TMEV-IDD; and naïve vs. CFA, PLP serum and brain samples. For naïve
vs. CFA vs. CFA+PLP-EAE only proteins that showed statistical difference between all the 3 groups were shown.
aCFA + PLP is significantly different from both Naïve and CFA alone.
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Figure 6 Cell ELISA of cytokine induced Neuro-Lymphatic protein expression on human brain neurovasculature in vitro. (A) Cell ELISA
of neuronal/lymphatic proteins in HBMEC-3 brain endothelial cells. IFN-γ= Interferon-gamma, IL-1β= Interleukin-beta, TNF-α= Tumor necrosis
factor-alpha. *P <0.05, #P close to significance (n=6-8). (B) Cell ELISA of neuronal/lymphatic proteins in SHSY-5Y neurons. IFN-γ= Interferon-gamma,
IL-1β= Interleukin-beta, TNF-α= Tumor necrosis factor-alpha. *P <0.05, #P close to significance (n=6-8).
Figure 5 PCA ordination diagram of the densitometric values from western analysis of six lymphatic proteins in the sera of con, RRMS,
and SPMS patients clustered the samples distinctly separate from each other.
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though, both VEGF-C and VEGF-D are ligands for
VEGFR-3, VEGF-C inhibition severely reduces the prolifer-
ation of VEGFR-3 expressing neural progenitor cells in
both xenopus tadpoles and in mice [55], indicating that
VEGF-C: VEGFR-3 axis functions in the stem cell signaling
in developing brain as well as in the pathophysiology of
CNS diseases like stroke. Since, VEGF-C and VEGFR-3
signaling has been shown to modulate innate and adaptive
immune responses in experimental obliterative bronchio-
litis [56], we expect that this VEGF-C: VEGFR-3 axis
might also play a key role in the pathophysiology of MS.
VEGF-D an important ligand for VEGFR-3 signaling
also plays an important role in the differentiation of human
pluripotent stem cells to dopaminergic neurons [57]. Fur-
thermore, VEGF-D plays an important role in neuronal
synaptic activity, dendritic length, and in the maintenance
of complex dendrite arborization via calcium dependent
calcium-calmodulin-dependent protein kinase IV signaling
[40]. Inhibition of mouse hippocampal VEGF-D result
in memory deficits indicating that calcium dependent
VEGF-D signaling is highly important for neuronal func-
tion and cognition [40]. Apart from its role in vasculature
Ang-2 was also shown to be involved in the regulation of
cortical neurogenesis in the telencephelon [39]. Inhibition
of Ang-2 in neuronal progenitor cells effects neuronal
migration, intermediate progenitor cells, and the surround-
ing vasculature in embryonic brain [39]. Furthermore,
Ang-2:Tie2: matrix metalloproteinases interactions play
an important role in the differentiation of neural progeni-
tor cells to neuronal lineage and migration of neuronal
progenitor cells in subventricular zone after stroke [38].
Our current findings showing that neuroinflammatory
diseases like MS can induce neuro-lymphatic protein
expression in the CNS gain more importance based on
the recent report showing a functional glymphatic system
involved in the clearance of fluids from the CNS diseases
[58-60]. While astrocytic aquaporin-4 plays a functional
role in the transparenchymal clearance of interstitial sol-
utes from the brain [60], it still remains unclear whether
astrocytes also express these common ‘neuro-lymphatic’
proteins in inflamed CNS. More importantly, whether this
common neuro-lymphatic protein expression is casual
bystander in the CNS inflammation or it participates in
interstitial solute clearance function of glympahtic system
needs further investigation. While the functional role of
these neuro-lymphatic protein expressions in pathophysi-
ology of CNS inflammation needs to be investigated,
physiologically these proteins play crucial role in the CNS
development and neuronal function.
Chronic autoimmune diseases like rheumatoid arthritis,
autoimmune thyroiditis, myasthenia gravis, Sjogren’s
syndrome, and MS are characterized by the formation of
ectopic follicle like structures and TLO structures in the
affected organs [19,20,23,24,30-32,61-67]. These TLOs
sustain inflammation via pro-inflammatory mediators, par-
ticipate in antigen presentation, generate auto-antibodies
and autoreactive T and B cells, and aggravate the disease
pathology. One of the main features of these TLOs is
the presence of lymphatic vessels and expression of
lymphoid chemokines including CCL12, CCL19, CCL21,
and CXCL13 which are shown to participate in lym-
phangiogenesis and lymphatic and immune interactions
[24,31,32,61,68-70]. It has been suggested that the number
of TLOs correlate with the disease pathology [23,24]. Even
though presence of lymphatics is one of the characteristic
features of TLOs, it is still not clear whether lymphatic
vasculature is present in the TLOs of MS brain/spinal tissue
[31,32,71]. However, we expect that a correlation can be
drawn between the neuronal/lymphatic protein alterations
(in the brain/spinal cord tissue) with TLOs formation,
disease severity, and type of MS.
One of the most important results of our study was the
observation that neurons in MS some patients express
LYVE-1. While the role of LYVE-1 in lymphatic vessels still
awaits investigation, neuronal LYVE-1 expression suggests
its potential physiological and pathological importance
in MS. Whether neuronal LYVE-1 is expressed in CNS
diseases besides MS also needs investigation. More im-
portantly, we observed dramatically higher numbers of
LYVE-1+ immune cells infiltrates in the MS brain vascula-
ture compared to normal brain vasculature. Previous
reports have shown CD11b+ myeloid cells express LYVE-1
and Prox-1 only when attached to the tumor vasculature
but not unattached, indicating that vascular-immune in-
teractions might play a prominent role in the expression
of these proteins in the immune cells [72-74]. This might
result in more complex interactions between infiltrating
immune cells and MS neurovasculature in lymphoid TLO
formation in MS. In addition to LYVE-1 immunostaining,
we observed a distinct D2-40 expression by immunohisto-
chemistry on normal brain blood vessels and an intense
D2-40 staining on and around microvessels (perivascular
positivity) in MS brains suggesting the use of D2-40 as an
inflammatory endothelial marker. Since podoplanin+ Th17
cells are shown to be the main contributors of TLOs
formation [20,23,24], we expect that in MS an increased
D2-40 staining around the vasculature may represent
future TLOs formation site due to the possible accumu-
lation of Th17 cells at the sites of vascular entry. While
TLOs formation was noticed in the brains of SPMS patients
but not in primary-progressive MS (PPMS) or RRMS by
Serafini et al. [19], intracerebral expression of CXCL13
and BAFF was shown to be accompanied by formation
of lymphoid like structures in animal model of relapsing
EAE [21].
However, since RRMS was described to have no TLOs
formation and we observe significant increase in these
protein profiles in both serum and brains of RRMS, we
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wanted to see if neurovasculature in MS might participate
in the induction of these proteins under inflammatory en-
vironment. Since we observed an increase in brain Prox-1
levels and IL-3 can re-induce expression of Prox-1 and
podoplanin in blood endothelial cells [50], we expect that
increased IL-3 levels in MS pathology might provoke
these changes and deserves further investigation. This was
based on the recent study that shows that IL-3 can induce
lymphatic specific Prox-1 in blood endothelium [50]. Taken
this into consideration, we hypothesized that increased
inflammatory environment in the MS brains might induce
alterations in these proteins in neurovasculature. To
confirm our hypothesis we performed cell ELISA using
neuroinflammatory cytokines including IL-3. We observed
a differential expression profile of these proteins in human
neurons and human brain endothelium suggesting complex
interactions of pro-inflammatory mediators with neurovas-
culature can induce alterations in these neuronal/lymphatic
proteins in MS brain neurovasculature.
Even though, we observed distinct brain endothelial
D2-40 staining in control and MS brains, none of the
in vitro stimuli showed an induction in D2-40 expression
indicating more complex roles of cytokine/chemokine/
growth factor signaling networks and infiltrating immune
cells in MS CNS. Of all the proteins under study, VEGF-D
showed significant induction in MS and MS animal
models (except PLP-EAE serum) and in neurovascular
inflammatory conditions in vitro. It was well known that
VEGF-D is one of the most potent lymphangiogenic fac-
tors [74]. Based on the result VEGF-D is the only growth
factor that is altered in all these conditions, we expect a
much complex role of VEGF-D in MS pathophysiology.
We expect that VEGF-D might also participate in forma-
tion and sustaining of TLOs in MS disease. Further exper-
iments to correlate VEGF-D levels with TLOs formation
and gain/loss of VEGF-D function studies in MS will shed
more light on its role in modulating neurovascular
damage in the pathophysiology of MS. Furthermore,
since some of these lymphatic specific proteins are
expressed by neurons and blood vessels, the functions
of these proteins in MS might be divergent, affecting
the functions of neurovascular interactions in the brain
and CNS-immune interactions. While our study showed
several important vascular (blood and lymphatic) and
common neuronal and lymphatic marker aberrations
in the MS and its animal models, the functional roles
of these proteins in the etiology, development, and progres-
sion of MS remains an important area of investigation.
Results from our western blotting analysis showed that
the expression levels of common neuronal/lymphatic
proteins in sera were significantly altered in demyelin-
ating diseases: MS, PLP-EAE, and TMEV-IDD. Using the
densitometry data from immunoblotting experiments,
we conducted unsupervised PCA to determine whether
controls and disease samples could be separated into
different groups by expression patterns of sets of these
neuronal/lymphatic proteins (‘unsupervised’ analysis, con-
ducted without information on samples; grouping was
conducted post-analysis). Since PCA of these proteins
resulted in grouping between controls and demyelinating
diseases (for example, PCA of sera among control, RRMS,
and SPMS clearly separated into three groups), these
proteins may be used as a ‘marker panel’ to discriminate
between controls and disease samples. While our current
results require further validation using larger sample size,
our results suggest that a set of these ‘protein panel’ in
serum represent a novel, powerful panel which would
discriminate between healthy subjects, RRMS, SPMS,
and possibly PPMS without sampling cerebrospinal fluid
or brain tissue. Correlating data from both mice and
humans, PCA can help us to find effective markers which
detect MS and provide an etiological basis of disease.
Besides the potential advantage of PCA to identify proteins
common to these pathologies that could serve to differenti-
ate MS subtypes (with much larger sample size and meas-
urement of the accurate protein levels) the functional roles
of these proteins in MS pathophysiology deserves further
investigation.
Conclusions
Our study shows that RRMS pathophysiology is also
accompanied with alterations in common neuronal/
lymphatic protein expression and that inflammation in-
duces the expression of these common neuronal/lymphatic
proteins significantly higher in neurons and in brain
endothelium. PCA results on the serum samples from
RRMS and SPMS indicated that the expression of neuro-
lymphatic protein profiles can separate both these MS
types from normal patients. However, we were limited by
small sample size and lack of SPMS brain samples. Larger
studies that include PPMS samples are needed to assess
whether these proteins can be used as a panel for differen-
tiating MS subtypes.
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Additional file 1: Table S1. Details of clinical diagnosis, gross, and
micro-neuropathological information and other neuropathological
symptoms of the postmortem MS patients’ brain samples.
Additional file 2: Figure S1. (A) Western blot images of D2-40, LYVE-1,
Prox-1, VEGFR-3, VEGF-D, and Ang-2 in control and RRMS brain tissue samples.
Con n=5, RRMS n=9. (B) Western blot images of D2-40, LYVE-1, Prox-1,
VEGFR-3, VEGF-D, and Ang-2 in control, RRMS, and SPMS serum samples.
Additional file 3: Figure S2. (A) Additional D2-40 immunostained
pictures of human postmortem control brain samples (3912, 4064, 4135,
and 3805) and MS brain samples (3816, 3840, 572, and 3422). D2-40
immunostaining is intense and focused at the perivascular endothelial
inflammatory region and parenchyma in all MS samples. (B) Additional
LYVE-1 immunostained pictures of human postmortem control samples
(3912, 4064, 4135, and 3805) and MS brain samples (3816, 3840, 572, and
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2946). Brain parenchyma stained positive for intensively positive for
LYVE-1 in MS sample 2946. Magnification 40×.
Additional file 4: Figure S3. (A) Western blot images of LYVE-1, Prox-1,
VEGFR-3, VEGF-D, and Ang-2 in randomly chosen control and TMEV-IDD
mice brain tissue samples. Con n=3, TMEV-IDD n=3. (B) Western blot
images of LYVE-1, Prox-1, VEGFR-3, VEGF-D, and Ang-2 in corresponding
serum samples from control and TMEV-IDD mice.
Additional file 5: Figure S4. (A)Western blot images of LYVE-1, Prox-1,
VEGFR-3, VEGF-D, and Ang-2 in randomly chosen naïve, CFA-treated,
and CFA+PLP-EAE mice brain tissue samples. Naïve n=3, CFA n=3,
CFA+PLP-EAE n=4. (B) Western blot images of LYVE-1, Prox-1, VEGFR-3,
VEGF-D, and Ang-2 in corresponding serum samples from naïve, CFA,
and CFA+PLP-EAE mice.
Additional file 6: Figure S5. Plot of the eigenvalues that reflect the
variance of the principal components showed that >90% of the variance
in this matrix of lymphatic proteins is contained in the first two principal
components (PC1, 61%; PC2, 28%). The factor loading on the eigenvalues
for PC1 and PC2 reflect the amount of variance shared by the parameter
with the PC1 and PC2 values.
Additional file 7: Figure S6. (A) Bar graphs showing the cytokine
(TNF-α, IL-1β, IFN-γ, and Il-3) mediated neuro-lymphatic protein expression
profiles in HBEMC-3 brain endothelial cells. (B) Bar graphs showing the
cytokine (TNF-α, IL-1β, IFN-γ, and Il-3) mediated neuro-lymphatic protein
expression profiles in SYSY-5Y neurons.
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